RS50358B - Osteoprotegerin vezujući proteini i receptori - Google Patents
Osteoprotegerin vezujući proteini i receptoriInfo
- Publication number
- RS50358B RS50358B YUP-506/99A YU50699A RS50358B RS 50358 B RS50358 B RS 50358B YU 50699 A YU50699 A YU 50699A RS 50358 B RS50358 B RS 50358B
- Authority
- RS
- Serbia
- Prior art keywords
- nucleic acid
- seq
- ssc
- receptors
- osteoprotegerin binding
- Prior art date
Links
- 102000008108 Osteoprotegerin Human genes 0.000 title abstract 2
- 108010035042 Osteoprotegerin Proteins 0.000 title abstract 2
- 108091008324 binding proteins Proteins 0.000 title abstract 2
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 title abstract 2
- 102000014914 Carrier Proteins Human genes 0.000 title 1
- 102000005962 receptors Human genes 0.000 title 1
- 108020003175 receptors Proteins 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 abstract 5
- 108020004707 nucleic acids Proteins 0.000 abstract 5
- 150000007523 nucleic acids Chemical class 0.000 abstract 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 abstract 2
- 241000972773 Aulopiformes Species 0.000 abstract 1
- 102000023732 binding proteins Human genes 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 235000019515 salmon Nutrition 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Analytical Chemistry (AREA)
Abstract
Izolovana nukelinska kiselina odabrana iz grupe koju čine: a) nukelinska kiselina koja kodira polipeptid na slici 1 (SEQ ID NO:2) ili slici 4 (SEQ ID NO:4); i b) nukleinska kiselina koja hibridizuje u komplementarnu nukleinsku kiselinu koja kodira protein na slici 1 (SEQ ID NO:2) ili slici 4 (SEQ ID NO:4) pod uslovima 5XSSPE, 50% formamid, 2X Denhardt'ov rastvor, 0.1% SDS i 100 μg/ml DNK sperme lososa u trajanju od 18-24 sati na 42°C i ostaje hibridizovana pod uslovima 2X SSC u trajanju od 10 min na sobnoj temperaturi, IX SSC u trajanju od 10 min na 50°C i 0.5X SSC u trajanju od 10 do 15 min., gde nukleinska kiselina kodira osteoprotegerin vezujući protein. Prijava sadrži još 12 nezavisnih i 22 zavisna patentna zahteva.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MEP-328/08A MEP32808A (en) | 1997-04-16 | 1998-04-15 | Osteoprotegerin binding proteins and receptors |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/842,842 US5843678A (en) | 1997-04-16 | 1997-04-16 | Osteoprotegerin binding proteins |
US88085597A | 1997-06-23 | 1997-06-23 | |
US09/052,521 US6316408B1 (en) | 1997-04-16 | 1998-03-30 | Methods of use for osetoprotegerin binding protein receptors |
Publications (2)
Publication Number | Publication Date |
---|---|
YU50699A YU50699A (sh) | 2000-10-30 |
RS50358B true RS50358B (sr) | 2009-11-10 |
Family
ID=27126366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YUP-506/99A RS50358B (sr) | 1997-04-16 | 1998-04-15 | Osteoprotegerin vezujući proteini i receptori |
Country Status (15)
Country | Link |
---|---|
US (4) | US6316408B1 (sr) |
EP (1) | EP2311955A3 (sr) |
JP (2) | JP2009001566A (sr) |
KR (2) | KR101314478B1 (sr) |
CN (1) | CN103990122B (sr) |
CA (1) | CA2706609A1 (sr) |
CY (1) | CY1108998T1 (sr) |
GE (1) | GEP20033002B (sr) |
IL (1) | IL132304A (sr) |
LT (1) | LTC0975754I2 (sr) |
ME (2) | ME00184B (sr) |
NO (1) | NO2010022I2 (sr) |
PT (1) | PT975754E (sr) |
RO (1) | RO122495B1 (sr) |
RS (1) | RS50358B (sr) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL117175A (en) * | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
AU5697098A (en) * | 1996-12-13 | 1998-07-03 | Schering Corporation | Mammalian cell surface antigens; related reagents |
DE69740107D1 (de) | 1996-12-23 | 2011-03-10 | Immunex Corp | Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie |
PT911342E (pt) * | 1997-04-15 | 2006-08-31 | Sankyo Co | Nova proteina e processo para a produzir |
SK288559B6 (sk) | 1997-04-16 | 2018-05-02 | Amgen, Inc. | Nukleová kyselina, polypeptid, expresný vektor a hostiteľská bunka; proteín viažuci osteoprotegerín a spôsob jeho prípravy, protilátka a liečivo na prevenciu alebo liečenie chorôb kostí |
US6316408B1 (en) * | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
JP2002514418A (ja) * | 1998-05-14 | 2002-05-21 | イミュネックス・コーポレーション | 破骨細胞活性の阻害方法 |
US20030103978A1 (en) * | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
MXPA03002443A (es) * | 2000-09-22 | 2004-12-06 | Immunex Corp | Ensayos de clasificacion para agonistas o antagonistas del activador receptor de nf-kb. |
US7425549B2 (en) * | 2001-02-06 | 2008-09-16 | The Royal Alexandra Hospital For Children | Drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis |
US20040132971A1 (en) * | 2001-02-09 | 2004-07-08 | Haaning Jesper Mortensen | Rank ligand-binding polypeptides |
AU2002231602A1 (en) * | 2001-02-09 | 2002-08-28 | Maxygen Holdings Ltd. | Rank ligand-binding polypeptides |
JP2005515159A (ja) * | 2001-06-06 | 2005-05-26 | イミュネックス・コーポレーション | 癌を治療するためのrankアンタゴニストの使用 |
EP2087908B1 (en) * | 2001-06-26 | 2018-05-30 | Amgen Inc. | Antibodies to opgl |
US6592606B2 (en) | 2001-08-31 | 2003-07-15 | Advanced Cardiovascular Systems, Inc. | Hinged short cage for an embolic protection device |
US8262689B2 (en) | 2001-09-28 | 2012-09-11 | Advanced Cardiovascular Systems, Inc. | Embolic filtering devices |
US20030109444A1 (en) * | 2001-10-12 | 2003-06-12 | Jonathan Lam | Bone anti-resorptive compounds |
US7241304B2 (en) | 2001-12-21 | 2007-07-10 | Advanced Cardiovascular Systems, Inc. | Flexible and conformable embolic filtering devices |
JP2005530482A (ja) * | 2002-01-04 | 2005-10-13 | ゼンコー・インコーポレイテッド | ドミナントネガティブタンパク質およびそれらの用法 |
US7381792B2 (en) * | 2002-01-04 | 2008-06-03 | Xencor, Inc. | Variants of RANKL protein |
US20040170602A1 (en) * | 2002-01-04 | 2004-09-02 | Desjarlais John R. | Dominant negative proteins and methods thereof |
WO2003086289A2 (en) | 2002-04-05 | 2003-10-23 | Amgen Inc. | Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors |
US7259143B2 (en) * | 2002-09-05 | 2007-08-21 | Wisconsin Alumni Research Foundation | Method of extending the dose range of vitamin D compounds |
US20080249068A1 (en) * | 2002-09-05 | 2008-10-09 | Deluca Hector F | Method of Extending the Dose Range of Vitamin D Compounds |
US7331973B2 (en) | 2002-09-30 | 2008-02-19 | Avdanced Cardiovascular Systems, Inc. | Guide wire with embolic filtering attachment |
WO2004052233A2 (en) * | 2002-12-10 | 2004-06-24 | Schering-Plough Ltd. | Canine rankl and methods for preparing and using the same |
US7344716B2 (en) * | 2003-05-13 | 2008-03-18 | Depuy Spine, Inc. | Transdiscal administration of specific inhibitors of pro-inflammatory cytokines |
US8361467B2 (en) * | 2003-07-30 | 2013-01-29 | Depuy Spine, Inc. | Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints |
US8895540B2 (en) | 2003-11-26 | 2014-11-25 | DePuy Synthes Products, LLC | Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor |
ATE544781T1 (de) * | 2004-12-13 | 2012-02-15 | Cephalon Australia Vic Pty Ltd | Osteoprotegerinvarianten-proteine |
PE20070684A1 (es) * | 2005-11-14 | 2007-08-06 | Amgen Inc | MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP |
US20080107597A1 (en) * | 2006-01-12 | 2008-05-08 | Anaptys Biosciences, Inc. | Isolation of antibodies that cross-react and neutralize rankl originating from multiple species |
WO2007130619A1 (en) * | 2006-05-03 | 2007-11-15 | The Trustees Of The University Of Pennsylvania | Compositions and methods for regulating osteoclast differentiation, activation and bone resorption |
WO2008088594A2 (en) * | 2007-01-12 | 2008-07-24 | Anaptysbio, Inc. | Isolation of antibodies that cross-react and neutralize rankl orginating from multiple species |
US8216209B2 (en) | 2007-05-31 | 2012-07-10 | Abbott Cardiovascular Systems Inc. | Method and apparatus for delivering an agent to a kidney |
CN101772351B (zh) * | 2007-06-05 | 2013-01-02 | 东方酵母工业株式会社 | 新的骨量增加药 |
US20090162351A1 (en) * | 2007-12-21 | 2009-06-25 | Depuy Spine, Inc. | Transdiscal administration of inhibitors of p38 MAP kinase |
US8986696B2 (en) * | 2007-12-21 | 2015-03-24 | Depuy Mitek, Inc. | Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints |
DK2626431T3 (en) | 2010-10-06 | 2015-12-21 | Fundació Inst De Recerca Biomèdica Irb Barcelona | A process for the diagnosis, prognosis and treatment of breast cancer metastasis |
PT3404041T (pt) * | 2011-04-19 | 2020-07-30 | Amgen Inc | Método para tratamento da osteoporose |
GB201118840D0 (en) | 2011-11-01 | 2011-12-14 | Univ Sheffield | Pulmonary hypertension II |
EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
US10006091B2 (en) | 2012-06-06 | 2018-06-26 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis |
US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
BR112015008255B1 (pt) | 2012-10-12 | 2023-02-28 | Inbiomotion S.L | Métodos in vitro para diagnóstico ou prognóstico de metástase óssea em um indivíduo com câncer de próstata e método para classificar um indivíduo que sofre de câncer de próstata em uma coorte |
UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
WO2014144817A2 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Inhibitory polypeptides specific to wnt inhibitors |
JP6577873B2 (ja) | 2013-03-15 | 2019-09-18 | フンダシオ、インスティトゥト、デ、レセルカ、ビオメディカ(イエレベ、バルセロナ)Fundacio Institut De Recerca Biomedica (Irb Barcelona) | がんの転移の予後診断および処置のための方法 |
WO2014184679A2 (en) | 2013-03-15 | 2014-11-20 | Inbiomotion S.L. | Method for the prognosis and treatment of renal cell carcinoma metastasis |
EP3712166A1 (en) | 2013-09-05 | 2020-09-23 | Amgen Inc. | Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles |
BR112016007864A2 (pt) | 2013-10-09 | 2017-12-05 | Fundacio Inst De Recerca Biomedica Irb Barcelona | método para a prognose e tratamento de metástase de câncer |
US10373702B2 (en) * | 2014-03-27 | 2019-08-06 | Massachusetts Institute Of Technology | Water-soluble trans-membrane proteins and methods for the preparation and use thereof |
JP6671298B2 (ja) | 2014-05-16 | 2020-03-25 | アムジェン インコーポレイテッド | Th1及びth2細胞集団を検出するためのアッセイ |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
AU2015358868A1 (en) | 2014-12-11 | 2017-06-01 | Inbiomotion S.L. | Binding members for human C-Maf |
IL255148B2 (en) | 2015-04-29 | 2023-04-01 | Radius Pharmaceuticals Inc | 1901 rad for use in a method to inhibit a cancerous growth or induce tumor regression in a patient who is resistant to the drug and/or has cancer positive for an estrogen receptor alpha mutation |
EP3901283A1 (en) | 2016-05-25 | 2021-10-27 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-maf status |
EP3474841B1 (en) | 2016-06-22 | 2022-03-16 | Ellipses Pharma Ltd | Ar+ breast cancer treatment methods |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
CN117417263A (zh) | 2017-01-05 | 2024-01-19 | 雷迪厄斯制药公司 | Rad1901-2hcl的多晶型形式 |
US11680101B2 (en) | 2017-01-27 | 2023-06-20 | Kymab Limited | Anti-OPG antibodies |
SG11201908328XA (en) | 2017-03-14 | 2019-10-30 | Amgen Inc | Control of total afucosylated glycoforms of antibodies produced in cell culture |
WO2019102380A1 (en) | 2017-11-22 | 2019-05-31 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-maf |
BR112020019559A2 (pt) | 2018-03-26 | 2021-01-12 | Amgen Inc. | Glicoformas afucosiladas totais de anticorpos produzidos em cultura de células |
CN112423844A (zh) | 2018-07-04 | 2021-02-26 | 雷迪厄斯制药公司 | Rad1901-2hcl的多晶型形式 |
TWI679439B (zh) * | 2018-10-01 | 2019-12-11 | 緯穎科技服務股份有限公司 | 電源管理系統及電源管理方法 |
BR112022005583A2 (pt) | 2019-09-26 | 2022-09-20 | Amgen Inc | Métodos para a produção de composições de anticorpos |
EP4110371A1 (en) | 2020-01-24 | 2023-01-04 | Radius Health, Inc. | Methods of stimulating bone growth with abalopartide and denosumab |
EP4162257A1 (en) | 2020-06-04 | 2023-04-12 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
MX2023004364A (es) | 2020-10-15 | 2023-05-03 | Amgen Inc | Glucanos no emparejados relativos en metodos de produccion de anticuerpos. |
WO2022261021A1 (en) | 2021-06-07 | 2022-12-15 | Amgen Inc. | Using fucosidase to control afucosylation level of glycosylated proteins |
AU2022361382A1 (en) | 2021-10-05 | 2024-03-28 | Amgen Inc. | Fc-gamma receptor ii binding and glycan content |
WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
Family Cites Families (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US595524A (en) * | 1897-12-14 | William clough | ||
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4710457A (en) * | 1983-06-29 | 1987-12-01 | Sloan-Kettering Institute For Cancer Research | Monoclonal antibody for human hematopoietic glycoproteins and method |
US4710473A (en) * | 1983-08-10 | 1987-12-01 | Amgen, Inc. | DNA plasmids |
WO1986000922A1 (en) | 1984-07-30 | 1986-02-13 | The Salk Institute For Biological Studies | Retroviral gene transfer vectors |
US4959314A (en) * | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
US6150090A (en) * | 1986-01-09 | 2000-11-21 | Massachusetts Institute Of Technology | Nuclear factors associated with transcriptional regulation |
US5846534A (en) * | 1988-02-12 | 1998-12-08 | British Technology Group Limited | Antibodies to the antigen campath-1 |
AU648505B2 (en) | 1989-05-19 | 1994-04-28 | Amgen, Inc. | Metalloproteinase inhibitor |
JP3356775B2 (ja) * | 1990-11-30 | 2002-12-16 | セルトリックス ファーマシューティカルズ, インコーポレイテッド | TGF―βとの共同的組合せによる骨修復のための骨形成タンパク質の使用 |
US5118667A (en) * | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
CA2068389A1 (en) | 1991-05-13 | 1992-11-14 | Masahiko Sato | Method for inhibiting bone resorption |
MX9204303A (es) * | 1991-07-23 | 1993-11-01 | Rhone Poulenc Rorer Int | Factor regulador del crecimiento de osteoclasto. |
IL99120A0 (en) | 1991-08-07 | 1992-07-15 | Yeda Res & Dev | Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them |
US5961974A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same |
AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5447851B1 (en) * | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
JPH07509223A (ja) | 1992-04-30 | 1995-10-12 | アムジェン インコーポレイテッド | インターロイキン−1媒介疾患および腫瘍壊死因子媒介疾患の治療方法 |
US5585479A (en) * | 1992-07-24 | 1996-12-17 | The United States Of America As Represented By The Secretary Of The Navy | Antisense oligonucleotides directed against human ELAM-I RNA |
US5578569A (en) * | 1993-03-12 | 1996-11-26 | Tam; Cherk S. | Method of increasing bone growth |
US5457035A (en) * | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
EP0725800B1 (en) * | 1993-09-14 | 2001-06-27 | Merck & Co. Inc. | cDNA ENCODING A NOVEL HUMAN PROTEIN TYROSINE PHOSPHATASE |
US6268212B1 (en) | 1993-10-18 | 2001-07-31 | Amgen Inc. | Tissue specific transgene expression |
US5641747A (en) * | 1994-07-25 | 1997-06-24 | Temple University-Of The Commonwealth System Of Higher Education | Treatment of osteopetrotic diseases |
AU708972B2 (en) | 1994-11-07 | 1999-08-19 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
EP0727211A1 (en) | 1995-02-10 | 1996-08-21 | Smithkline Beecham Corporation | Use of src SH2 specific compounds to treat a bone resorption disease |
IL117175A (en) | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
US6001349A (en) | 1995-02-22 | 1999-12-14 | Therion Biologics Corporation | Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof |
WO1996028546A1 (en) | 1995-03-15 | 1996-09-19 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor |
US20030166097A1 (en) * | 1995-03-15 | 2003-09-04 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor |
US7094564B1 (en) * | 1995-03-15 | 2006-08-22 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor |
EP0822984A4 (en) | 1995-04-27 | 2000-05-03 | Human Genome Sciences Inc | TUMOR NECROSIS FACTOR RECEPTORS IN MEN |
WO1997000318A1 (en) | 1995-06-07 | 1997-01-03 | Osteosa Inc. | Osteoclast growth regulatory factor |
US5843901A (en) * | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
AU5985996A (en) | 1995-06-07 | 1997-01-15 | Osteosa Inc. | Osteoclast growth regulatory factor |
KR100510234B1 (ko) | 1995-06-29 | 2005-11-25 | 임뮤넥스 코포레이션 | 세포소멸을 유도하는 시토킨 |
US6613544B1 (en) * | 1995-12-22 | 2003-09-02 | Amgen Inc. | Osteoprotegerin |
US6369027B1 (en) | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
US6046048A (en) * | 1996-01-09 | 2000-04-04 | Genetech, Inc. | Apo-2 ligand |
US5981220A (en) * | 1996-03-27 | 1999-11-09 | Human Genome Sciences, Inc. | Epidermal differentiation factor |
TW555765B (en) | 1996-07-09 | 2003-10-01 | Amgen Inc | Low molecular weight soluble tumor necrosis factor type-I and type-II proteins |
JPH1057071A (ja) | 1996-08-19 | 1998-03-03 | Snow Brand Milk Prod Co Ltd | 新規dna及びそれを用いた蛋白質の製造方法 |
AU5697098A (en) * | 1996-12-13 | 1998-07-03 | Schering Corporation | Mammalian cell surface antigens; related reagents |
WO1998028423A2 (en) | 1996-12-20 | 1998-07-02 | Board Of Regents, The University Of Texas System | Compositions and methods of use for osteoclast inhibitory factors |
FR2757507B1 (fr) | 1996-12-20 | 1999-01-29 | Inst Francais Du Petrole | Procede de separation de paraxylene comprenant une adsorption avec injection d'eau et une cristallisation |
US6271349B1 (en) * | 1996-12-23 | 2001-08-07 | Immunex Corporation | Receptor activator of NF-κB |
DE69740107D1 (de) * | 1996-12-23 | 2011-03-10 | Immunex Corp | Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie |
PT911342E (pt) * | 1997-04-15 | 2006-08-31 | Sankyo Co | Nova proteina e processo para a produzir |
US5843678A (en) * | 1997-04-16 | 1998-12-01 | Amgen Inc. | Osteoprotegerin binding proteins |
US6316408B1 (en) * | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
SK288559B6 (sk) | 1997-04-16 | 2018-05-02 | Amgen, Inc. | Nukleová kyselina, polypeptid, expresný vektor a hostiteľská bunka; proteín viažuci osteoprotegerín a spôsob jeho prípravy, protilátka a liečivo na prevenciu alebo liečenie chorôb kostí |
CA2229449A1 (en) * | 1997-04-25 | 1998-10-25 | Takeda Chemical Industries, Ltd. | Novel receptor protein and its use |
CA2288351A1 (en) | 1997-05-01 | 1998-11-05 | Amgen Inc. | Chimeric opg polypeptides |
WO1998054201A1 (en) | 1997-05-29 | 1998-12-03 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like protein 8 |
JPH119269A (ja) | 1997-06-19 | 1999-01-19 | Kaken Pharmaceut Co Ltd | 破骨細胞系細胞 |
US6087555A (en) | 1997-10-15 | 2000-07-11 | Amgen Inc. | Mice lacking expression of osteoprotegerin |
US7063960B2 (en) * | 1997-12-12 | 2006-06-20 | The Rockefeller University | Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof |
WO1999029865A2 (en) | 1997-12-12 | 1999-06-17 | The Rockefeller University | A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof |
US6790823B1 (en) | 1998-04-23 | 2004-09-14 | Amgen Inc. | Compositions and methods for the prevention and treatment of cardiovascular diseases |
JP2002514418A (ja) | 1998-05-14 | 2002-05-21 | イミュネックス・コーポレーション | 破骨細胞活性の阻害方法 |
HUP0102492A2 (hu) | 1998-06-19 | 2001-11-28 | Smithkline Beecham Corp. | Amino-indanon származékok alkalmazása NF-kB transzkripciós faktor inhibitor hatású gyógyszerkészítmények előállítására |
HUP0102782A3 (en) | 1998-06-19 | 2002-12-28 | Smithkline Beecham Corp | Salycilanilide as inhibitors of transcription factor nf-kb |
ID28386A (id) * | 1998-09-15 | 2001-05-17 | M & E Biotech As | Metode penurunan aktivitas ligan osteoprotegerin |
AU6078500A (en) | 1999-07-09 | 2001-01-30 | Amgen, Inc. | Combination therapy for conditions leading to bone loss |
EP1140136B1 (en) | 1999-09-03 | 2007-05-16 | Amgen Inc. | Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer |
US20030144187A1 (en) | 1999-09-03 | 2003-07-31 | Colin R. Dunstan | Opg fusion protein compositions and methods |
AUPQ314799A0 (en) | 1999-09-29 | 1999-10-21 | University Of Western Australia, The | Bone cell factor |
DK2105449T3 (da) | 2000-02-23 | 2019-10-07 | Amgen Inc | Antagonistiske selektive bindemidler af osteoprotegerinbindende protein |
US20030103978A1 (en) * | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
AU2001286586A1 (en) | 2000-08-18 | 2002-03-04 | University Of Massachusetts Medical Center | Trance regulation of chondrocyte differentiation |
EP1458411A4 (en) | 2000-08-21 | 2004-09-22 | Smithkline Beecham Corp | ANTI-RANK LIGAND MONOCLONAL ANTIBODIES SUITABLE FOR THE TREATMENT OF RANK LIGAND RELATED DISORDERS |
MXPA03002443A (es) * | 2000-09-22 | 2004-12-06 | Immunex Corp | Ensayos de clasificacion para agonistas o antagonistas del activador receptor de nf-kb. |
US20030017151A1 (en) * | 2001-05-17 | 2003-01-23 | Dougall William C. | Therapeutic use of rank antagonists |
JP2005515159A (ja) * | 2001-06-06 | 2005-05-26 | イミュネックス・コーポレーション | 癌を治療するためのrankアンタゴニストの使用 |
EP2087908B1 (en) * | 2001-06-26 | 2018-05-30 | Amgen Inc. | Antibodies to opgl |
US7084257B2 (en) * | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
US7183069B2 (en) | 2002-03-07 | 2007-02-27 | Toyama University | Reagent, method and apparatus for measuring amylase activity |
WO2003086289A2 (en) * | 2002-04-05 | 2003-10-23 | Amgen Inc. | Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors |
EP1566816A4 (en) | 2002-11-27 | 2007-04-04 | Yazaki Corp | CABLE AND METHOD FOR IDENTIFYING CABLES |
-
1998
- 1998-03-30 US US09/052,521 patent/US6316408B1/en not_active Expired - Lifetime
- 1998-04-15 KR KR1019997009492A patent/KR101314478B1/ko not_active IP Right Cessation
- 1998-04-15 EP EP10184791A patent/EP2311955A3/en not_active Withdrawn
- 1998-04-15 RO RO99-01101A patent/RO122495B1/ro unknown
- 1998-04-15 ME MEP-2008-328A patent/ME00184B/me unknown
- 1998-04-15 PT PT98918244T patent/PT975754E/pt unknown
- 1998-04-15 CN CN201310463795.5A patent/CN103990122B/zh not_active Expired - Lifetime
- 1998-04-15 CA CA2706609A patent/CA2706609A1/en not_active Abandoned
- 1998-04-15 GE GEAP19985034A patent/GEP20033002B/en unknown
- 1998-04-15 RS YUP-506/99A patent/RS50358B/sr unknown
- 1998-04-15 KR KR1020127021477A patent/KR101328809B1/ko not_active IP Right Cessation
- 1998-04-15 ME MEP-328/08A patent/MEP32808A/xx unknown
- 1998-12-14 US US09/211,297 patent/US7807795B2/en not_active Expired - Fee Related
- 1998-12-14 US US09/211,315 patent/US7097834B1/en not_active Expired - Lifetime
-
1999
- 1999-10-08 IL IL132304A patent/IL132304A/en active Protection Beyond IP Right Term
-
2004
- 2004-04-15 US US10/825,898 patent/US20050003400A1/en not_active Abandoned
-
2007
- 2007-06-21 CY CY20071100833T patent/CY1108998T1/el unknown
-
2008
- 2008-06-11 JP JP2008153218A patent/JP2009001566A/ja not_active Withdrawn
-
2010
- 2010-11-24 LT LTPA2010013C patent/LTC0975754I2/lt unknown
- 2010-11-25 NO NO2010022C patent/NO2010022I2/no unknown
-
2012
- 2012-09-13 JP JP2012201172A patent/JP2013028622A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US6316408B1 (en) | 2001-11-13 |
LTPA2010013I1 (lt) | 2021-05-25 |
US20050003400A1 (en) | 2005-01-06 |
JP2009001566A (ja) | 2009-01-08 |
YU50699A (sh) | 2000-10-30 |
NO2010022I1 (no) | 2011-01-10 |
MEP32808A (en) | 2010-10-10 |
KR20010006405A (ko) | 2001-01-26 |
GEP20033002B (en) | 2003-06-25 |
LTC0975754I2 (lt) | 2022-03-25 |
EP2311955A3 (en) | 2012-12-12 |
US20030100488A1 (en) | 2003-05-29 |
PT975754E (pt) | 2007-08-20 |
IL132304A (en) | 2015-07-30 |
CN103990122A (zh) | 2014-08-20 |
KR101328809B1 (ko) | 2014-01-17 |
CY1108998T1 (el) | 2014-07-02 |
CN103990122B (zh) | 2017-01-04 |
EP2311955A2 (en) | 2011-04-20 |
US7807795B2 (en) | 2010-10-05 |
NO2010022I2 (no) | 2015-03-30 |
JP2013028622A (ja) | 2013-02-07 |
ME00184B (me) | 2010-10-10 |
KR20120108046A (ko) | 2012-10-04 |
CA2706609A1 (en) | 1998-10-22 |
US7097834B1 (en) | 2006-08-29 |
KR101314478B1 (ko) | 2014-01-17 |
RO122495B1 (ro) | 2009-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RS50358B (sr) | Osteoprotegerin vezujući proteini i receptori | |
Wallner et al. | Cloning and expression of human lipocortin, a phospholipase A2 inhibitor with potential anti-inflammatory activity | |
Guerini et al. | Cloning of human calcineurin A: evidence for two isozymes and identification of a polyproline structural domain. | |
WO1998055508A3 (en) | HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS | |
CA2300358A1 (en) | Novel phytase | |
PT655890E (pt) | Celulas recombinantes, construcoes de adn, vectores e metodos para expressao de enzimas degradantes de fitato em proporcoes desejadas | |
WO1995000551B1 (en) | Prostaglandin receptor fp and dna encoding it | |
WO2000034474A3 (en) | Growth factor homolog zvegf3 | |
DE69937570D1 (de) | Transformierender wachstumsfaktor beta-9 (ztgfss9) aus säugetieren | |
KR950702577A (ko) | 아젤레높시스 아페르타(agelenopsis aperta)로 부터의 칼슘 채널 차단 폴리펩티드(calcium channel blocking polypeptide from agelenopsis aperta) | |
CA2011008C (en) | Egf variants and pharmaceutical use thereof | |
ATE287952T1 (de) | Humanes thymosin beta 15 gen,protein und dessen verwendungen | |
AU6378994A (en) | Plant promoter, microorganisms and plant cells containing a unit for the expression of a protein of interest comprising said promoter | |
Joubert | Snake Venom Toxins: The Amino‐Acid Sequences of Three Toxins (9B, 11 and 12A) from Hemachatus haemachatus (Ringhals) Venom | |
WO2000063415A8 (en) | Dna encoding the human vanilloid receptor vr1 | |
WO1999009054A3 (en) | Peroxisome-associated polypeptide, nucleotide sequence encoding said polypeptide and their uses in the diagnosis and/or the treatment of lung injuries and diseases, and of oxidative stress-related disorders | |
AU3711597A (en) | A novel galanin receptor | |
DE69734596D1 (de) | "smoothened" proteine aus wirbeltieren | |
Shapiro et al. | A comparison of the membrane-bound and extracellular cyclic AMP phosphodiesterases of Dictyostelium discoideum | |
FI953688A (fi) | Proteiini, jolla on kasvinsuojelullisia ominaisuuksia | |
ATE148744T1 (de) | Neue thrombininhibitorische proteine aus landblutegeln | |
WO2001034653A3 (fr) | Proteine presente a la surface des cellules souches hematopoietiques de la lignee lymphoide et des cellules nk, et ses applications. | |
EP0724453A1 (en) | The cloning of duffy blood group antigen | |
WO2001059108A3 (en) | Inhibitors of apoptosis | |
CA1224169A (en) | Dna coding for a signal peptide and dna containing the same |